This acquisition of SimplicityBio will allow Precision for Medicine to add artificial intelligence to its clinical data management and analysis platform QuartzBio™. The American company currently employs more than 1,800 people on 30 sites in North America and Europe.
“Artificial intelligence approaches are only as good as the data we can apply them to ; joining Precision for Medicine and integrating our AI algorithms into QuartzBio™. is a giant leap forward for our customers and industry, as multiomic data grows in quantity and complexity”, says Matthew Hall, CEO and co-founder of SimplicityBio.
“We are thrilled to add SimplicityBio’s AI approach to our QuartzBio translational informatics platform. Integrating our industry-leading multiomics data processing and harmonization capabilities with proven artificial intelligence analytical tools is truly unique in the marketplace and allows us to offer an unrivaled solution for our biopharmaceutical clients”, explains Chad Clark, president of Precision for Medicine.
Industry leader in AI-powered healthcare
Established in Valais in 2015, SimplicityBio has moved its offices to the BioArk technology site in Monthey to benefit from the advanced infrastructure necessary for its development and has joined the start-up incubator of The Ark.
Over the years, with the support of The Ark and through winning multiple awards (Liechti Foundation, Venture Kick, FIT grant...), SimplicityBio has established itself as an industry leader in the emerging field of AI-based healthcare.